Several possible studies
Story checked
Weekly cisplatin fails to show fewer serious side effects in p16-negative head and neck cancer (opens in a new tab)
medicalxpress.com · 2026-10-04
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Weekly cisplatin fails to show fewer serious side effects in p16-negative head and neck cancer
medicalxpress.com · 2026-10-04
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Points somewhere elsepresented as the new finding
First Report from NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16+ Phase II Toxicity Results
- Cited as backgroundmentioned without context
First Report from NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16+ Phase II Toxicity Results
International Journal of Radiation Oncology*Biology*Physics · 2026
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedBefore NRG-HN009, there was limited randomized evidence to determine which cisplatin schedule provided the best balance of cancer control and treatment-related side effects in locally advanced head and neck cancer.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 8Not checkedIn the phase II portion of NRG-HN009, weekly cisplatin failed to show significantly lower acute toxicity than cisplatin given every three weeks in patients with p16-negative disease.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 8Not checkedBecause the study did not meet its predefined criteria for reduced acute toxicity with weekly cisplatin, the p16-negative cohort did not advance to the phase III portion of the trial.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 8Not checkedThe trial enrolled 234 eligible patients with p16-negative squamous cell carcinoma of the head and neck and randomized them to 70 Gy radiation with cisplatin every three weeks or weekly cisplatin.View evidenceHide evidence
As stated234 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 8Not checkedThe primary endpoint was acute toxicity measured by T-score, defined as the number of treatment-related grade 3-4 adverse events during treatment or within six months.View evidenceHide evidence
As statedT-score ratio 1.11; p=0.77
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 8Not checkedThe arms differed by at least 5% in several acute grade 3-4 adverse events, with more nausea, dehydration and acute kidney injury in the every-three-weeks arm and more decreased white blood cell counts and magnesium levels in the weekly arm.View evidenceHide evidence
As stated≥5% in several adverse events
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 8Not checkedSix-month locoregional failure rates were 4.6% in the every-three-weeks arm and 9.6% in the weekly arm.View evidenceHide evidence
As statedabsolute difference 5.0%
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 8Not checkedThe results were presented at the 2026 American Society for Radiation Oncology Annual Meeting and appear in the International Journal of Radiation Oncology*Biology*Physics.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
Crossref, PubMed, Europe PMC · 28 candidate papers
First Report from NRG-HN009 Randomized Phase II/III Trial of RT + Cisplatin Q3 Weeks vs RT + Cisplatin Weekly for Patients with Locoregionally Advanced SCCHN: p16+ Phase II Toxicity Results
International Journal of Radiation Oncology*Biology*Physics · 2026 · Crossref
Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial.
International Journal of Radiation Oncology, Biology, Physics · 2026 · PubMed, Europe PMC
Multidisciplinary Radiopharmaceutical Therapy Symposium (RPT): Author index
International Journal of Radiation Oncology*Biology*Physics · 2026 · Crossref
Pretreatment Chromosomal Instability Correlates With Radiation Sensitivity in Squamous Cell Cancers.
International Journal of Radiation Oncology, Biology, Physics · 2026 · PubMed, Europe PMC
ASTRO's 68th Annual Meeting - Index by Author
International Journal of Radiation Oncology*Biology*Physics · 2026 · Crossref
And 23 more candidates considered.